Mitotic kinesin inhibitors
View Patent ↗The present invention relates to dihydropyrazole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
1. A compound of Formula I:
or a pharmaceutically acceptable salt or stereoisomer thereof, wherein
a is 0 or 1; b is 0 or 1; m is 0, 1, or 2; n is 0 to 2; u is 4, 5 or 6;
is piperazine, which is optionally substituted with from one to six R 7 groups;
R 1 is selected from: 1) hydrogen; 2) (C═O) a O b C 1 -C 10 alkyl, 3) (C═O) a O b aryl, 4) CO 2 H, 5) halo, 6) CN, 7) OH, 8) O b C 1 -C 6 perfluoroalkyl, 9) O a (C═O) b NR 8 R 9 , 10) S(O) m R a , 11) S(O) 2 NR 8 R 9 , and 12) —OPO(OH) 2 ;
said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R 7 ;
R 2 is selected from: 1) hydrogen; 2) C 1 -C 10 alkyl; 3) C 1 -C 10 alkyl-O—R d , 4) C 2 -C 10 alkenyl-O—R d , 5) C 2 -C 10 alkynyl-O—R d , 6) (C 1 -C 6 -alkylene) n C 3 -C 8 cycloalkyl-O—R d , 7) C 1 -C 10 alkyl-(C═O) b —NR c R c ′, 8) C 2 -C 10 alkenyl-(C═O) b NR c R c ′, 9) C 2 -C 10 alkynyl-(C═O) b NR c R c ′, 10) (C 1 -C 6 -alkylene) n C 3 -C 8 cycloalkyl-(C═O) b NR c R c ′, 11) C 1 -C 10 alkyl-S(O) m —R d , 12) C 2 -C 10 alkenyl-S(O) m —R d , 13) C 2 -C 10 alkynyl-S(O) m —R d , and 14) (C 1 -C 6 -alkylene) n C 3 -C 8 cycloalkyl-S(O) m —R d ,
said alkyl, alkenyl, alkynyl and cycloalkyl are optionally substituted with one or more substituents selected from R 6 ;
R 3 is independently selected from: 1) (C═O) a O b C 1 -C 10 alkyl, 2) (C═O) a O b aryl, 3) CO 2 H, 4) halo, 5) CN, 6) H, 7) O b C 1 -C 6 perfluoroalkyl, 8) O a (C═O) b NR 8 R 9 , 9) S(O) m R a , 10) S(O) 2 NR 8 R 9 , and 11) —OPO(OH) 2 ;
said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R 7 ;
R 4 and R 5 are independently selected from: 1) H, 2) C 1 -C 10 alkyl, 3) aryl, 4) C 2 -C 10 alkenyl, 5) C 2 -C 10 alkynyl, 6) C 1 -C 6 perfluoroalkyl, 7) C 1 -C 6 aralkyl, 8) C 3 -C 8 cycloalkyl, and 9) heterocyclyl,
said alkyl, aryl, alkenyl, alkynyl, cycloalkyl, aralkyl and heterocyclyl is optionally substituted with one or more substituents selected from R 7 ; or
R 4 and R 5 attached to the same carbon atom are combined to form —(CH 2 ) u — wherein one of the carbon atoms is optionally replaced by a moiety selected from O, S(O) m , —N(R 9 )C(O)—, and —N(COR 10 )—;
R 6 is independently selected from: 1) (C═O) a O b C 1 -C 10 alkyl, 2) (C═O) a O b aryl, 3) C 2 -C 10 alkenyl, 4) C 2 -C 10 alkynyl, 5) (C═O) a O b heterocyclyl, 6) CO 2 H, 7) halo, 8) CN, 9) OH, 10) O b C 1 -C 6 perfluoroalkyl, 11) O a (C═O) b NR 8 R 9 , 12) S(O) m R a , 13) S(O) 2 NR 8 R 9 , 14) oxo, 15) CHO, 16) (N═O)R 8 R 9 , 17) (C═O) a O b C 3 -C 8 cycloalkyl, and 18) —OPO(OH) 2 ;
said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R 7 ;
R 7 is selected from: 1) (C═O) r O s (C 1 -C 10 )alkyl, 2) O r (C 1 -C 3 )perfluoroalkyl, 3) oxo, 4) OH, 5) halo, 6) CN, 7) (C 2 -C 10 )alkenyl, 8) (C 2 -C 10 )alkynyl, 9) (C═O) r O s (C 3 -C 6 )cycloalkyl, 10) (C═O) r O s (C 0 -C 6 )alkylene-aryl, 11) (C═O) r O s (C 0 -C 6 )alkylene-heterocyclyl, 12) (C═O) r O s (C 0 -C 6 )alkylene-N (R b ) 2 , 13) C(O)R a , 14) (C 0 -C 6 )alkylene-CO 2 R a , 15) C(O)H, 16) (C 0 -C 6 )alkylene-CO 2 H, and 17) (C═O) r N(R b ) 2 , 18) S(O) m R a , 19) S(O) 2 N(R b ) 2 ; and 20) —OPO(OH) 2 ;
said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, alkylene and heterocyclyl is optionally substituted with up to three substituents selected from R b , OH, (C 1 -C 6 )alkoxy, halogen, CO 2 H, CN, O(C═O) C 1 -C 6 alkyl, oxo, NO 2 and N(R b ) 2 ;
R 8 and R 9 are independently selected from: 1) H, 2) (C═O)O b C 1 -C 10 alkyl, 3) (C═O)O b C 3 -C 8 cycloalkyl, 4) (C═O)O b aryl, 5) (C═O)O b heterocyclyl, 6) C 1 -C 10 alkyl, 7) aryl, 8) C 2 -C 10 alkenyl, 9) C 2 -C 10 alkynyl, 10) heterocyclyl, 11) C 3 -C 8 cycloalkyl, 12) SO 2 R a , and 13) (C═O)NR b 2 ,
said alkyl, cycloalkyl, aryl, heterocylyl, alkenyl, and alkynyl is optionally substituted with one, two or three substituents selected from R 7 , or
R 8 and R 9 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one, two or three substituents selected from R 7 ;
R a is (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, aryl, or heterocyclyl; and
R b is H, (C 1 -C 6 )alkyl, aryl, heterocyclyl, (C 3 -C 6 )cycloalkyl, (C═O)OC 1 -C 6 alkyl, (C═O)C 1 -C 6 alkyl or S(O) 2 R a .
2. The compound according to claim 1 of the Formula I:
wherein
is:
optionally substituted with from one to three R 7 groups; and
R 7 ′ is:
1) H,
2) C 1 -C 10 alkyl,
3) aryl,
4) C 2 -C 10 alkenyl,
5) C 2 -C 10 alkynyl,
6) heterocyclyl,
7) OH,
8) C 1 -C 6 perfluoroalkyl,
9) C 3 -C 8 cycloalkyl;
10) (C═O)C 1 -C 10 alkyl, and
11) S(O) m C 1 -C 10 alkyl;
said alkyl, aryl, alkenyl, alkynyl and heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R b , OH, (C 1 -C 6 )alkoxy, halogen, CO 2 H, CN, O(C═O)C 1 -C 6 alkyl, oxo, NO 2 and N(R b ) 2 ; and
wherein a, b, m, n, u, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R a and R b are defined as in claim 1 for the compound of the Formula I.
3. The compound according to claim 1 of the Formula II:
wherein:
a is 0 or 1; b is 0 or 1; m is 0, 1, or 2; n is 0 to 2; u is 4, 5 or 6;
is piperazine, which is optionally substituted with from one to six R 7 groups;
R 1 is selected from: 1) 2) hydrogen; 3) (C═O) a O b C 1 -C 10 alkyl, 4) (C═O) a O b aryl, 5) CO 2 H, 6) halo, 7) CN, 8) OH, 9) O b C 1 -C 6 perfluoroalkyl, 10) O a (C═O) b NR 8 R 9 , 11) S(O) m R a , 12) S(O) 2 NR 8 R 9 , and 13) —OPO(OH) 2 ;
said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R 7 ;
R 2 is hydrogen or C 1 -C 10 alkyl, said alkyl optionally substituted with one or more substituents selected from R 6 ;
R 3 is independently selected from: 1) (C═O) a O b C 1 -C 10 alkyl, 2) (C═O) a O b aryl, 3) CO 2 H, 4) halo, 5) CN, 6) OH, 7) O b C 1 -C 6 perfluoroalkyl, 8) O a (C═O) b NR 8 R 9 , 9) S(O) m R a , 10) S(O) 2 NR 8 R 9 , and 11) —OPO(OH) 2 ;
said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R 7 ;
R 4 is selected from: H, C 1 -C 10 alkyl, wherein said alkyl is optionally substituted with one or more substituents selected from R 7 ;
R 6 is independently selected from: 1) (C═O) a O b C 1 -C 10 alkyl, 2) (C═O) a O b aryl, 3) C 2 -C 10 alkenyl, 4) C 2 -C 10 alkynyl, 5) (C═O) a O b heterocyclyl, 6) CO 2 H, 7) halo, 8) CN, 9) OH, 10) O b C 1 -C 6 perfluoroalkyl, 11) O a (C═O) b NR 8 R 9 , 12) S(O) m R a , 13) S(O) 2 NR 8 R 9 , 14) oxo, 15) CHO, 16) (N═O)R 8 R 9 , 17) (C═O) a O b C 3 -C 8 cycloalkyl, and 18) —OPO(OH) 2 ;
said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R 7 ;
R 7 is selected from: 1) (C═O) r O s (C 1 -C 10 )alkyl, 2) O r (C 1 -C 3 )perfluoroalkyl, 3) oxo, 4) OH, 5) halo, 6) CN, 7) (C 2 -C 10 )alkenyl, 8) (C 2 -C 10 )alkynyl, 9) (C═O) r O s (C 3 -C 6 )cycloalkyl, 10) (C═O) r O s (C 0 -C 6 )alkylene-aryl, 11) (C═O) r O s (C 0 -C 6 )alkylene-heterocyclyl, 12) (C═O) r O s (C 0 -C 6 )alkylene-N(R b ) 2 , 13) C(O)R a , 14) (C 0 -C 6 )alkylene-CO 2 R a , 15) C(O)H, 16) (C 0 -C 6 )alkylene-CO 2 H, 17) (C═O) r N(R b ) 2 , 18) S(O) m R a , 19) S(O) 2 N(R b ) 2 ; and 20) —OPO(OH) 2 ;
said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, alkylene and heterocyclyl is optionally substituted with up to three substituents selected from R b , OH, (C 1 -C 6 )alkoxy, halogen, CO 2 H, CN, O(C═O)C 1 -C 6 alkyl, oxo, NO 2 and N(R b ) 2 ;
R 8 and R 9 are independently selected from: 1) H, 2) (C═O)O b C 1 -C 10 alkyl, 3) (C═O)O b C 3 -C 8 cycloalkyl, 4) (C═O)O b aryl, 5) (C═O)O b heterocyclyl, 6) C 1 -C 10 alkyl, 7) aryl, 8) C 2 -C 10 alkenyl, 9) C 2 -C 10 alkynyl, 10) heterocyclyl, 11) C 3 -C 8 cycloalkyl, 12) SO 2 R a , and 13) (C═O)NR b 2 ,
said alkyl, cycloalkyl, aryl, heterocylyl, alkenyl, and alkynyl is optionally substituted with one, two or three substituents selected from R 7 , or
R 8 and R 9 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one, two or three substituents selected from R 7 ;
R a is (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, aryl, or heterocyclyl; and
R b is H, (C 1 -C 6 )alkyl, aryl, heterocyclyl, (C 3 -C 6 )cycloalkyl, (C═O)OC 1 -C 6 alkyl, (C═O)C 1 -C 6 alkyl or S(O) 2 R a .
4. The compound according to claim 3 of the Formula II:
wherein
is selected from:
optionally substituted with from one to three R 7 groups; and
R 7 ′ is:
1) H,
2) C 1 -C 10 alkyl,
3) aryl,
4) C 2 -C 10 alkenyl,
5) C 2 -C 10 alkynyl,
6) heterocyclyl,
7) OH,
8) C 1 -C 6 perfluoroalkyl,
9) C 3 -C 8 cycloalkyl;
10) (C═O)C 1 -C 10 alkyl, and
11) S(O) m C 1 -C 10 alkyl;
said alkyl, aryl, alkenyl, alkynyl and heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R b , OH, (C 1 -C 6 )alkoxy, halogen, CO 2 H, CN, O(C═O)C 1 -C 6 alkyl, oxo, NO 2 and N(R b ) 2 ; and
wherein a, b, m, n, u, R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R a and R b are defined as in claim 3 for the compound of the Formula II.
5. A compound selected from:
1-((1S)-1-{[(5S)-3-(2,5-difluorophenyl)-5-methyl-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl]carbonyl}propyl)-4-methylpiperazine;
1-{(1S)-2-[(5S)-3-(2,5-difluorophenyl)-5-methyl-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl]-1-methyl-2-oxoethyl}-4-methylpiperazine;
1-(1-{[3-(2,5-difluorophenyl)-5-methyl-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl]carbonyl}butyl)-4-methylpiperazine;
1-acetyl-4-(1-{[3-(2,5-difluorophenyl)-5-methyl-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl]carbonyl}propyl)piperazine;
(3R)-1-{2-[3-(2,5-difluorophenyl)-5-methyl-5-phenyl-4,5-dihydro-1H-pyrazol -1-yl]-1-methyl-2-oxoethyl}-3-methylpiperazine;
(3S)-1-{2-[3-(2,5-difluorophenyl)-5-methyl-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl]-1-methyl-2-oxoethyl}-3-methylpiperazine;
1-(1-{[3-(2,5-difluorophenyl)-5-methyl-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl]carbonyl}propyl)piperazine;
1-{2-[3-(2,5-difluorophenyl)-5-methyl-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl]-1-methyl-2-oxoethyl}piperazine;
1-acetyl-4-{2-[3-(2,5-difluorophenyl)-5-methyl-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl]-1-methyl-2-oxoethyl}piperazine;
1-{2-[3-(2,5-difluorophenyl)-5-methyl-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl]-1-methyl-2-oxoethyl}-4-(methylsulfonyl)piperazine;
1-{2-[3-(2,5-difluorophenyl)-5-methyl-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl]-1-methyl-2-oxoethyl}-4-[2-(methylsulfonyl)ethyl]piperazine;
1-{2-[3-(2,5-difluorophenyl)-5-methyl-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl]-1-methyl-2-oxoethyl}-4-(2-oxo-2-pyrrolidin-1-ylethyl)piperazine;
1-{2-[3-(2,5-difluorophenyl)-5-methyl-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl]-1-methyl-2-oxoethyl}-4-(2-methoxyethyl)piperazine;
1-(1-{[3-(2,5-difluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl]carbonyl}propyl)-4-methylpiperazine;
1-(1-{[3-(2,5-difluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl]carbonyl}butyl)-4-methylpiperazine;
{3-(2,5-difluorophenyl)-1-[2-(4-methylpiperazin-1-yl)propanoyl]-5-phenyl-4,5-dihydro-1H-pyrazol-5-yl}methanol;
or a pharmaceutically acceptable salt or stereoisomer thereof.
6. A compound selected from:
1-acetyl-4-(1-{[3-(2,5-difluorophenyl)-5-methyl-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl]carbonyl}propyl)piperazine TFA salt.
7. A pharmaceutical composition that is comprised of a compound in accordance with claim 1 and a pharmaceutically acceptable carrier.